%53%61%6d%73%75%6e%67%20%4d%65%64%69%63%61%6c%20%43%65%6e%74%65%72
-
KAIST to Develop a Korean-style ChatGPT Platform Specifically Geared Toward Medical Diagnosis and Drug Discovery
On May 23rd, KAIST (President Kwang-Hyung Lee) announced that its Digital Bio-Health AI Research Center (Director: Professor JongChul Ye of KAIST Kim Jaechul Graduate School of AI) has been selected for the Ministry of Science and ICT's 'AI Top-Tier Young Researcher Support Program (AI Star Fellowship Project).' With a total investment of ₩11.5 billion from May 2025 to December 2030, the center will embark on the full-scale development of AI technology and a platform capable of independently inferring and determining the kinds of diseases, and discovering new drugs.
< Photo. On May 20th, a kick-off meeting for the AI Star Fellowship Project was held at KAIST Kim Jaechul Graduate School of AI’s Yangjae Research Center with the KAIST research team and participating organizations of Samsung Medical Center, NAVER Cloud, and HITS. [From left to right in the front row] Professor Jaegul Joo (KAIST), Professor Yoonjae Choi (KAIST), Professor Woo Youn Kim (KAIST/HITS), Professor JongChul Ye (KAIST), Professor Sungsoo Ahn (KAIST), Dr. Haanju Yoo (NAVER Cloud), Yoonho Lee (KAIST), HyeYoon Moon (Samsung Medical Center), Dr. Su Min Kim (Samsung Medical Center) >
This project aims to foster an innovative AI research ecosystem centered on young researchers and develop an inferential AI agent that can utilize and automatically expand specialized knowledge systems in the bio and medical fields.
Professor JongChul Ye of the Kim Jaechul Graduate School of AI will serve as the lead researcher, with young researchers from KAIST including Professors Yoonjae Choi, Kimin Lee, Sungsoo Ahn, and Chanyoung Park, along with mid-career researchers like Professors Jaegul Joo and Woo Youn Kim, jointly undertaking the project. They will collaborate with various laboratories within KAIST to conduct comprehensive research covering the entire cycle from the theoretical foundations of AI inference to its practical application.
Specifically, the main goals include: - Building high-performance inference models that integrate diverse medical knowledge systems to enhance the precision and reliability of diagnosis and treatment. - Developing a convergence inference platform that efficiently combines symbol-based inference with neural network models. - Securing AI technology for new drug development and biomarker discovery based on 'cell ontology.'
Furthermore, through close collaboration with industry and medical institutions such as Samsung Medical Center, NAVER Cloud, and HITS Co., Ltd., the project aims to achieve: - Clinical diagnostic AI utilizing medical knowledge systems. - AI-based molecular target exploration for new drug development. - Commercialization of an extendible AI inference platform.
Professor JongChul Ye, Director of KAIST's Digital Bio-Health AI Research Center, stated, "At a time when competition in AI inference model development is intensifying, it is a great honor for KAIST to lead the development of AI technology specialized in the bio and medical fields with world-class young researchers." He added, "We will do our best to ensure that the participating young researchers reach a world-leading level in terms of research achievements after the completion of this seven-year project starting in 2025."
The AI Star Fellowship is a newly established program where post-doctoral researchers and faculty members within seven years of appointment participate as project leaders (PLs) to independently lead research. Multiple laboratories within a university and demand-side companies form a consortium to operate the program.
Through this initiative, KAIST plans to nurture bio-medical convergence AI talent and simultaneously promote the commercialization of core technologies in collaboration with Samsung Medical Center, NAVER Cloud, and HITS.
2025.05.26 View 15155 -
KAIST Opens Cell Bench Research Center
KAIST opened a cell bench research center on the campus on Monday, Nov. 17, as a joint project with Samsung Electric Co. and Samsung Medical Center.
On hand at the opening ceremony were about 100 persons from the three organizations, including KAIST President Nam-Pyo Suh, Samsung Electric"s Chief Technology Officer (CTO) Byung-Cheon Koh and Samsung Medical Center Vice President Hyo-Geun Lim.
The newly-opened research center will be involved in the development of individually-tailored anti-cancer medicine using bio-inspired cell chips and technologies for clinical applications. Prof. Young-Ho Cho of the Department of Bio and Brain Engineering was named director of the research center.
"Top-notch professionals from the electronic industry, academia and the medical community have gathered together to establish this research center. We expect the center will open a new path for the science and technology community and the industry to combine their strengths and develop innovative anti-cancer therapeutics," said KAIST President Nam-Pyo Suh at the opening ceremony.
"The development of bio-cell chip technology represents a new challenge for the Samsung Electric which has focused on information technologies thus far. Through cooperation with KAIST and Samsung Medical Center, we expect to be able to develop a simple and efficient cure for cancer patients," commented Samsung Electric CTO Byung-Cheon Koh.
The research center will be initially concentrating on the development of cell chips for lung cancer, one of the primary causes of death for Koreans.
2008.11.17 View 24539